Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders

Vox Sanguinis

Volumn 98, Issue 3 PART. 2, 2010, Pages 385-394

  Imbach, P ^a   Lazarus, A H ^b   Kuhne T ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Autoimmune disorders; Immune thrombocytopenia; Intravenous immunoglobulin; Mechanism of actions

Indexed keywords

CD40 LIGAND; COLONY STIMULATING FACTOR 1; FAS ANTIBODY; FC RECEPTOR; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; AUTOIMMUNE DISEASE; BLOOD EXAMINATION; CELL MATURATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY DISEASE; INFUSION RATE; LYMPHOCYTE FUNCTION; MACROPHAGE; MACROPHAGE ACTIVATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; X LINKED AGAMMAGLOBULINEMIA;

AUTOIMMUNE DISEASES; CYTOKINES; DENDRITIC CELLS; FORECASTING; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLAMMATION; LYMPHOCYTE SUBSETS; MACROPHAGES; PHAGOCYTOSIS; RECEPTORS, IGG;

EID: 77949414304     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2009.01264.x     Document Type: Review

References (141)

1. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-1231
2. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, Mueller-Eckhardt C, Müller B, Rossi E, Barandun S: Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; 2:464-468
3. Newland AC, Trealeaven JG, Minchinton RM, Waters AH: High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1:84-87
4. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H: T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123-1124
5. Imbach P, Kühne T, Signer E: Historical aspects and current knowledge of idiopathic thrombocytopenic purpura. Br J Haematol 2002; 119:894-900
6. Lemieux R, Bazin R, Néron S: Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42:839-848. Review
7. Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006; 253(Suppl 5):V18-V24
8. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27:233-245
9. Kieseier BC, Meyer Zu Hörste G, Lehmann HC, Gold R, Hartung HP: Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol 2008; 21:555-562
10. Hartung HP: Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255(Suppl 3):3-6. Review
11. Hughes R: The role of IVIg in autoimmune neuropathies: the latest evidence. J Neurol 2008; 255(Suppl 3):7-11. Review
12. Jolles S, Hughes J: Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol 2006; 6:579-591. Review
13. Carbone J: Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2:9-18
14. Schleis TG: The process: new methods of purification and viral safety. Pharmacotherapy 2005; 25(11 pt 2):73S-77S
15. Bjøro K, Frøland SS, Yun Z, Samdal HH, Haaland T: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:1607-1611
16. Svae TE, Neisser-Svae A, Bailey A, Reichl H, Biesert L, Schmidt T, Heger A, Römisch J: Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apher Sci 2008; 39:59-67
17. Ofosu FA, Freedman J, Semple JW: Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99:851-862. Review
18. Sorensen R: Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm 2007; 13:278-283
19. Epstein JS, Zoon KC: Important drug warning: Immune Globulin Intravenous (human) (IGIV) products. Neonatal Netw 2000; 19:60-62
20. Centers for Disease Control and Prevention (CDC): Renal insufficiency and failure associated with immune globulin intravenous therapy. Morbid Mortal Weekly Rep 1999; 48:1985-1998
21. Vucic S, Chong PS, Dawson KT, Cudkowicz M, Cros D: Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol 2004; 52:141-144
22. Bonilla FA: Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122:1238-1239
23. Ryan ME, Webster ML, Statler JD: Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr (Phila) 1996; 35:23-31
24. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr: The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60:1822-1824
25. Hamrock DJ: Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6:535-542
26. Dalakas MC: High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44:223-226
27. Hooper JA: Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008; 28:765-778. viii
28. Seite JF, Shoenfeld Y, Youinou P, Hillion S: What is the contents of the magic draft IVIg? Autoimmun Rev 2008; 7:435-439
29. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J: Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342:678
30. Blasczyk R, Westhoff U, Grosse-Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341:789-790
31. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO: Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007; 1110:426-432. Review
32. St-Amour I, Laroche A, Bazin R, Lemieux R: Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GMCSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol 2009; 133:52-60
33. Crow AR, Lazarus AH: The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 2008; 22:103-116. Review
34. Nimmerjahn F, Ravetch JV: Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-533. Review
35. Kaveri SV, Lacroix-Desmazes S, Bayry J: The antiinflammatory IgG. N Engl J Med 2008; 359:307-309
36. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, Bleeker WK: Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimmers: studies in experimental immune thrombocytopenia. Blood 2001; 98:1095-1099
37. Rossi F, Kazatchkine MD: Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989; 143:4104-4109
38. Siragam V, Brine D, Crow AR, Song S, Freedman J, Lazarus AH: Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 115:155-160
39. Siragam V, Crow AR, Brine D, Song S, Freedman J, Lazarus AH: Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat Med 2006; 12:688-692
40. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV: Colonystimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18:573-581
41. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, Delignat S, Varambally S, Oksenhendler E, Lévy Y, Debré M, Kazatchkine MD, Hermine O, Kaveri SV: Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 2004; 101:14210-14215
42. Misra N, Bayry J, Dasgupta S, Ephrem A, Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Intravenous immunoglobulin and dendritic cells. Clin Rev Allergy Immunol 2005; 29:201-205
43. Banchereau J, Schuler-Thurner B, Palucka AK et al.: Dendritic cells as vectors for therapy. Cell 2001; 106:271-274
44. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101:758-765
45. Brigl M, Brenner MB: CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22:817-890
46. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998; 392:245-252
47. Smed-Sörensen A, Moll M, Cheng TY, Loré K, Norlin AC, Perbeck L, Moody DB, Spetz AL, Sandberg JK: IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa. Blood 2008; 111:5037-5046
48. Cao X, Sugita M, Van Der Wel N, Lai J, Rogers RA, Peters PJ, Brenner MB: CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J Immunol 2002; 169:4770-4777
49. Kuwana M, Kawakami Y, Ikeda Y: Suppression of autoreactive T-cell response to glycoprotein IIb-IIIa by blockade of CD40 . CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 2003; 101:621-623
50. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229:152-172
51. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ: CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22:307-328
52. Simister NE, Mostov KE: An Fc receptor structurally related to MHC class 1 antigens. Nature 1989; 337:184-187
53. Ghetie V, Ward ES: Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000; 18:739-766
54. Roopenian DC, Akilesh S: FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-725
55. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering disease. J Clin Invest 2005; 115:3440-3450
56. Hansen RJ, Balthasar JP: Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88:898-899
57. Liu L, Garcia AM, Santoro H, Zhang Y, McDonell K, Dumont J, Bitontl A: Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol 2007; 178:5390-5398
58. Delfraissy JF, Tchernia G, Laurian Y et al.: Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60:315-322
59. Maccy Mg, Newland AC: CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol 1990; 76:513-520
60. Tsubakio T, Kurata Y, Katagiri S, Kanakura Y, Tamaki T, Kuyama J, Kanayama Y, Yonezawa T, Tarui S: Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patints with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983; 53:697-702
61. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, Toubi E: Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179:5571-5575
62. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N: Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111:715-722
63. Aukrust P, Frøland SS, Liabakk NB, Müller F, Nordøy I, Haug C, Espevik T: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-2143
64. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH: A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 2007; 109:155-158
65. Aubin E, Lemieux R, Bazin R: Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura. Br J Haematol 2007; 136:837-843
66. Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K: Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008; 112:1325-1328
67. Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, Jia H, Yang R, Han ZC: Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78:139-143
68. Semple JW: ITP three R's: regulation, routing, rituximab. Blood 2008; 112:927-928
69. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S: Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110:2924-2930
70. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, Kaneko H, Yamashina M, Kato Y, Orii T: Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11:152-158
71. Dussault N, Ducas E, Racine C, Jacques A, Paré I, Côté S, Néron S: Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2. Int Immunol 2008; 20:1369-1379
72. Sigman K, Ghibu F, Sommerville W, Toledano BJ, Bastein Y, Cameron L, Hamid QA, Mazer B: Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998; 102:421-427
73. de Grandmont MJ, Racine C, Roy A, Lemieux R, Néron S: Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003; 101:3065-3073
74. Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV: V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol Rev 1994; 139:79-107
75. Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-673
76. Fehr J, Hofmann V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by highdose intravenous gamma globulin. N Engl J Med 1982; 306:1254-1258
77. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC: Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986; 314:1236-1239
78. Samuelsson A, Towers T, Ravetch J: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-486
79. Nimmerjahn F, Ravetch JV: The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204:11-15
80. Crow AR, Song S, Siragam V, Lazarus AH: Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 2006; 47(5 Suppl):710-713. Review
81. Chang J, Shi PA, Chiang EY, Frenette PS: Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111:915-923
82. Mollnes TE, Høgå sen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R: High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48:312-317
83. Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ: Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004; 103:465-472
84. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD: F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9:431-438
85. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-493
86. Altznauer F, von Gunten S, Späth P, Simon HU: Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003; 112:1185-1190
87. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV: Therapeutic preparations of normal polyspecific IgG (IVIG) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIG involving the Fas apoptotic pathway. J Immunol 1998; 161:3781-3790
88. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H: Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000; 96:2520-2527
89. Press R, Nennesmo I, Kouwenhoven M, Huang YM, Link H, Pashenkov M: Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 2005; 159:165-176
90. Leung DY: Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996; 104(Suppl 1):49-54
91. Lau AC, Duong TT, Ito S, Yeung RS: Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009; 60:2131-2141
92. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP: Immunmodulatory and antimicrobial efficacy of intraveous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-712
93. Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol 2003; 10:165-169. Review
94. Caccavelli L, Field AC, Betin V, Dreillard L, Belair MF, Bloch MF, Bruneval P, Kazatchkine M, Bellon B: Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells. Eur J Immunol 2001; 31:2781-2790
95. Larroche C, Bruneel F, André MH, Bader-Meunier B, Barchel A, Tribout B, Genereau T, Zunic P: Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP. Ann Med Interne (Paris) 2000; 151:533-539
96. Berchtold P, Date GL, Tani P, McMillan R: Inhibition of autoantibody binding to platelet glycoprotein Iib . IIIa by anti-idiotype antibodies in intravenous gammaglobulin. Blood 1989; 74:2414-2417
97. Gianella-Borradori A, Hirt A, Lüthy A, Wagner HP, Imbach P: Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease. Treatment with intravenous immunoglobulin. A case report. Blut 1984; 48:403-407
98. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44
99. Reed E, Hardy M, Benvenisty A, Lattes C, Brensilver J, McCabe R, Reemstma K, King DW, Suciu-Foca N: Effect of anti-idiotypic antibodies on graft survival in renal allograft recipients. N Engl J Med 1987; 316:1450
100. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ: Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002; 26:549-552
101. Linker RA, Gold R: Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 2008; 21:358-365. Review
102. Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J: Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura; relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87:4245-4254
103. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290
104. Toubi E, Kessel A, Shoenfeld Y: High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005; 66:395-402
105. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of highdose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000
106. Ahmed AR, Sami N: Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002; 46:42-49
107. Engineer L, Ahmed AR: Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001; 44:818-828
108. Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Förster J, Bröcker EB, Saurat JH, French LE: Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207:96-99
109. Buchwald B, Weishaupt A, Toyka KV, Dudel J: Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998; 10:281-290
110. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ: Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126:2220-2234
111. Magnus T, Chan A, Savill J, Toyka KV, Gold R: Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002; 130:1-9
112. Van Schaik IN, Winer JB, De Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; 2:CD001797
113. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lünemann JD: Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA 2009; 106:4788-4792
114. Hughes RA: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert Rev Neurother 2009; 9:789-795
115. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE: Multifocal motor neuropathy improved by IVIG: randomized, double blind placebo-controlled study. Neurology 2003; 55:1256-1262
116. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting sclerosis. Lancet 1997; 349:589-593
117. Fazekas F, Sørensen PS, Filippi M, Ropele S, Lin X, Koelmel HW, Fernandez O, Pozzilli C, O'Connor P, Enriquez MM, Hommes OR; ESIMS: MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 2005; 11:433-440
118. Lewańska M, Siger-Zajdel M, Selmaj K: No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9:565-572
119. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398-402
120. Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Brenner T, Laub O, Souroujon MC: Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. Ann N Y Acad Sci 2008; 1132:244-248
121. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, Cervera R, Font J, Fridkin M, Thiesen HJ, Shoenfeld Y: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19:857-865
122. Solomon B: Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease. Rejuvenation Res 2008; 11:349-357
123. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH: Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75:1472-1474
124. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ: High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2009; [Epub ahead of print]
125. Michael D, Grando SA: Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses. Curr Dir Autoimmun 2008; 10:333-343. Review
126. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772-1779
127. Fernandez AP, Kerdel FA: The use of i.v. IG therapy in dermatology. Dermatol Ther 2007; 20:288-305. Review
128. Emilia G, Morselli M, Luppi M et al.: Long-term salvage therapy with cyclosporin A in refractory immune thrombocytopenic purpura. Blood 2002; 99:1482-1485
129. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P: Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112:999-1004
130. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV: Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-376
131. Leong H, Stachnik J, Bonk ME, Matuszewski KA: Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008; 65:1815-1824
132. George JN, Woolf SH, Raskob GE et al.: Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for The American Society of Hematology. Blood 1996; 88:3-40
133. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in Adults, Children and Pregnancy. Br J Haematol 2003; 120:574-596
134. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR; for the Intercontinental Childhood ITP Study Group: Newly diagnosed idiopathic thrombocytopenic purpura in childhood, an observational study. Lancet 2001; 358:2122-2125
135. Kühne T, Imbach P: A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from The Intercontinental Childhood ITP Study Group (ICIS). J Pediatr 2003; 143:605-608
136. Imbach P, Kühne T, Müller D, Berchtold W, Zimmerman S, Elalfy M, Buchanan GR: Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46:351-356
137. Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld EJ, Vesely SK, Adix L, Blanchette VS, Kühne T; Intercontinental Childhood ITP Study Group Registry II Participants: Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112:4003-4008
138. Kühne T, Blanchette V, Buchanan GR, Ramenghi U, Donato H, Tamminga RY, Rischewski J, Berchtold W, Imbach P; Intercontinental Childhood ITP Study Group: Splenectomy in children with idiopathic thrombocytopenic purpura. A prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007; 49:829-834
139. Foster CB, Zhu S, Erichsen HC, Lehrnbecher T, Hart ES, Choi E, Stein S, Smith MW, Steinberg SM, Imbach P, Kühne T, Chanock SJ: Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune Thrombocytopenic Purpura: a pilot study. Br J Haematol 2001; 113:596-599
140. Rioux JD, Abbas AK: Paths to understanding the genetic basis of autoimmune disease. Nature 2005; 435:584-589. Review
141. Smith AJ, Keen LJ, Billingham MJ, Perry MJ, Elson CJ, Kirwan JR, Sims JE, Doherty M, Spector TD, Bidwell JL: Extended haplotypes and linkage disequilibrium in the IL1R1-IL1AIL1B-IL1RN gene cluster: association with knee osteoarthritis. Genes Immun 2004; 5:451-460